213 related articles for article (PubMed ID: 29535035)
1. Inflammatory arthritis in pediatric patients with morphea.
Kashem SW; Correll CK; Vehe RK; Hobday PM; Binstadt BA; Maguiness SM
J Am Acad Dermatol; 2018 Jul; 79(1):47-51.e2. PubMed ID: 29535035
[TBL] [Abstract][Full Text] [Related]
2. Pediatric morphea (localized scleroderma): review of 136 patients.
Christen-Zaech S; Hakim MD; Afsar FS; Paller AS
J Am Acad Dermatol; 2008 Sep; 59(3):385-96. PubMed ID: 18571769
[TBL] [Abstract][Full Text] [Related]
3. Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG).
Bağlan E; Kızıldağ Z; Çağlayan Ş; Çakmak F; Yener GO; Özdel S; Öztürk K; Makay B; Çakan M; Ayaz NA; Sözeri B; Ünsal ŞE; Bülbül M
Clin Rheumatol; 2023 Oct; 42(10):2855-2860. PubMed ID: 37378874
[TBL] [Abstract][Full Text] [Related]
4. [Localized scleroderma (morphea)].
Bono W; Dupin N
Presse Med; 2006 Dec; 35(12 Pt 2):1923-8. PubMed ID: 17159718
[TBL] [Abstract][Full Text] [Related]
5. Pediatric morphea.
Browning JC
Dermatol Clin; 2013 Apr; 31(2):229-37. PubMed ID: 23557652
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of long-term outcomes in adults with pediatric-onset morphea.
Saxton-Daniels S; Jacobe HT
Arch Dermatol; 2010 Sep; 146(9):1044-5. PubMed ID: 20855712
[No Abstract] [Full Text] [Related]
7. Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.
Arthur M; Fett NM; Latour E; Jacobe H; Kunzler E; Florez-Pollack S; Houser J; Sharma S; Prasad S; Femia A; Stern MJ; Pappas-Taffer LK; Gaffney R; Fernandez AP; Knabel D; Cardones AR; Leung N; Laumann A; Yu JM; Zhao J; Vleugels RA; Tkachenko E; Lo K
JAMA Dermatol; 2020 May; 156(5):521-528. PubMed ID: 32236497
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study: Impact of consensus treatment plans on systemic therapy of pediatric morphea.
Do N; Ringold S; Sullivan E; Brandling-Bennett H
Pediatr Dermatol; 2020 Mar; 37(2):278-283. PubMed ID: 31967352
[TBL] [Abstract][Full Text] [Related]
9. Morphea and Eosinophilic Fasciitis: An Update.
Mertens JS; Seyger MMB; Thurlings RM; Radstake TRDJ; de Jong EMGJ
Am J Clin Dermatol; 2017 Aug; 18(4):491-512. PubMed ID: 28303481
[TBL] [Abstract][Full Text] [Related]
10. Natural history and extracutaneous involvement of congenital morphea: Multicenter retrospective cohort study and literature review.
Mansour M; Liy Wong C; Zulian F; Li S; Morishita K; Yeh EA; Stewart K; Laxer RM; Pope E
Pediatr Dermatol; 2018 Nov; 35(6):761-768. PubMed ID: 30187959
[TBL] [Abstract][Full Text] [Related]
11. Interventions for morphea.
Albuquerque JV; Andriolo BN; Vasconcellos MR; Civile VT; Lyddiatt A; Trevisani VF
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD005027. PubMed ID: 31309547
[TBL] [Abstract][Full Text] [Related]
12. Clinicohistopathological correlations in juvenile localized scleroderma: studies on a subset of children with hypopigmented juvenile localized scleroderma due to loss of epidermal melanocytes.
Sung JJ; Chen TS; Gilliam AC; McCalmont TH; Gilliam AE
J Am Acad Dermatol; 2011 Aug; 65(2):364-373. PubMed ID: 21570153
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993.
Peterson LS; Nelson AM; Su WP; Mason T; O'Fallon WM; Gabriel SE
J Rheumatol; 1997 Jan; 24(1):73-80. PubMed ID: 9002014
[TBL] [Abstract][Full Text] [Related]
14. Connective tissue nevus misdiagnosed as juvenile localized scleroderma.
Tirelli F; Giraudo C; Soliani M; Calabrese F; Martini G; Gisondi P; Meneghel A; Zulian F
Pediatr Rheumatol Online J; 2023 Oct; 21(1):125. PubMed ID: 37848914
[TBL] [Abstract][Full Text] [Related]
15. Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort.
Kunzler E; Florez-Pollack S; Teske N; O'Brien J; Prasad S; Jacobe H
J Am Acad Dermatol; 2019 Jun; 80(6):1664-1670.e1. PubMed ID: 31005342
[TBL] [Abstract][Full Text] [Related]
16. Low effectiveness of methotrexate in the management of localised scleroderma (morphea) based on an ultrasound activity score.
Vera-Kellet C; Meza-Romero R; Moll-Manzur C; Ramírez-Cornejo C; Wortsman X
Eur J Dermatol; 2021 Dec; 31(6):813-821. PubMed ID: 35107072
[TBL] [Abstract][Full Text] [Related]
17. An Evaluation of the Performance of Current Morphea Subtype Classifications.
Prasad S; Zhu JL; Schollaert-Fitch K; Torok KS; Jacobe HT
JAMA Dermatol; 2021 Apr; 157(4):1-8. PubMed ID: 33595618
[TBL] [Abstract][Full Text] [Related]
18. Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations.
Chiu YE; Shmuylovich L; Kiguradze T; Anderson K; Sibbald C; Tollefson M; Kunzler E; Tom WL; Bond K; Ahmad RC; Garcia-Romero MT; Irfan M; Kollman K; Hunt R; Stein SL; Arkin L; Wong V; Pope E; Jacobe H; Brandling-Bennett HA; Cordoro KM; Bercovitch L; Rangel SM; Liu X; Szabo A; Paller AS
J Am Acad Dermatol; 2021 Jul; 85(1):38-45. PubMed ID: 33689776
[TBL] [Abstract][Full Text] [Related]
19. Localized scleroderma: a clinical study at a single center in Korea.
Noh JW; Kim J; Kim JW
Int J Rheum Dis; 2013 Aug; 16(4):437-41. PubMed ID: 23992265
[TBL] [Abstract][Full Text] [Related]
20. Linear morphea overlying site of previous lichen aureus in a pediatric patient.
Johnston M; Benson P; Morley K
Pediatr Dermatol; 2019 Jul; 36(4):e91-e92. PubMed ID: 30994203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
